SNDX
Syndax Pharmaceuticals Inc

3,756
Mkt Cap
$1.91B
Volume
1.68M
52W High
$22.73
52W Low
$8.58
PE Ratio
-6.00
SNDX Fundamentals
Price
$22.14
Prev Close
$21.71
Open
$21.61
50D MA
$20.83
Beta
1.16
Avg. Volume
1.33M
EPS (Annual)
-$3.29
P/B
16.35
Rev/Employee
$578,362.42
$1,771.37
Loading...
Loading...
News
all
press releases
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $57.00 Price Target at Citigroup
Citigroup increased their target price on Syndax Pharmaceuticals from $51.00 to $57.00 and gave the company a "buy" rating in a report on Monday...
MarketBeat·7h ago
News Placeholder
More News
News Placeholder
Syndax Pharmaceuticals (NASDAQ:SNDX) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen lowered Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·3d ago
News Placeholder
Syndax Pharmaceuticals Q4 Earnings Call Highlights
Syndax Pharmaceuticals (NASDAQ:SNDX) executives highlighted a transformational year in 2025 during the company's fourth-quarter earnings call, pointing to momentum from two commercial launches...
MarketBeat·4d ago
News Placeholder
Syndax Pharmaceuticals (NASDAQ:SNDX) Announces Quarterly Earnings Results, Misses Expectations By $0.12 EPS
Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts...
MarketBeat·4d ago
News Placeholder
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of -21.88% and +10.21%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Insights into Syndax Pharmaceuticals Q4 Earnings
read more...
Benzinga·4d ago
News Placeholder
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twelve analysts that are covering the stock, Marketbeat.com reports. One...
MarketBeat·5d ago
News Placeholder
Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Monday
Syndax Pharmaceuticals (NASDAQ:SNDX) will be releasing its Q4 2025 earnings before the market opens on Monday, March 2. (View Earnings Report at...
MarketBeat·8d ago
News Placeholder
Aberdeen Group plc Grows Position in Syndax Pharmaceuticals, Inc. $SNDX
Aberdeen Group plc raised its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 22.9% in the third quarter, according to the company in its most recent disclosure with the...
MarketBeat·10d ago
News Placeholder
Syndax Pharmaceuticals Highlights Revuforj, Niktimvo Sales Surge and 2026 Milestones at Guggenheim Conf
Syndax Pharmaceuticals (NASDAQ:SNDX) executives told investors at a Guggenheim biotech conference that the company entered 2026 with what CEO Michael Metzger called a fantastic start, pointing to...
MarketBeat·16d ago
<
1
2
...
>

Latest SNDX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.